Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

ARNA 4.51 -0.05 (-1.10%)
price chart
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surging on Rumors?  HotStocked
3 Reasons to Buy VIVUS  DailyFinance
Related articles »  
Arena Buyout Rumors Are Overblown
What happens when a small pharmaceutical company hitches its wagon to a drug that finally gains FDA approval? The stock runs, and images of dollars raining down upon the smart early investors cloud reality.
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Related articles »  
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation
There has been an interesting trend among three noteworthy pharmaceutical companies like Arena Pharmaceuticals, Inc.
Vivus Looks Into European Approval As Company Pins Hopes On Qsymia  Seeking Alpha
Will pill-popping beat obesity?  Stuff.co.nz
Related articles »  
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
What Slims Down Fastest After Diet Drugs Are Approved by he FDA? Two Stocks ...  YCharts
Related articles »  
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Related articles »  
5 Bio-Pharma Stocks To Buy Right Here
The company is making money now or close to it, has diverse products (hormone delivery, arthritis, contraception...), and long term nestragel and male contraceptives could be really huge (women preferred their contraceptive gel to a pill 3-1).
Related articles »  
Short Interest in Biotech Firms on the Rise
Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date.
Related articles »  
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Buying SGYP today after IRWD approval still makes sense just above $5/share. Retail investors have been pounded when trying to play bank-shots off of competitor FDA approvals in recent months.
Related articles »  
Earnings Preview: Orexigen Therapeutics
On June 27, 2012, Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the U.S. Food and Drug Administration has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight ...